Side Effects

Ozempic and Thyroid Cancer Risk: What You Need to Know

You've probably seen the black box warning on Ozempic's label mentioning thyroid tumors, and if you're like most people, it stopped you in your tracks. It's completely understandable to feel worried when considering a medication that carries any cancer warning, especially one as serious as thyroid cancer.

Let's walk through what we actually know about Ozempic and thyroid cancer risk, what the research tells us, and how to make an informed decision about whether GLP-1 medications are right for you.

Understanding the Black Box Warning

Ozempic (semaglutide) carries a boxed warning—the FDA's most serious type—about thyroid C-cell tumors. This warning exists because in animal studies, rats and mice given semaglutide developed thyroid tumors called medullary thyroid carcinoma (MTC). These tumors appeared at doses much higher than humans typically receive, but the finding was significant enough to warrant the warning.

Here's the important context: these were animal studies, not human cases. The doses given to rodents were often many times higher than what's prescribed for diabetes or weight loss in people. Rodents also have different thyroid physiology than humans, which may make them more susceptible to these effects.

What the Human Research Shows

Since Ozempic and similar GLP-1 medications have been on the market, researchers have been carefully monitoring for any signs of increased thyroid cancer in humans. The good news is that large-scale studies haven't found a clear link.

Real-World Data

Multiple studies examining thousands of patients taking semaglutide and other GLP-1 medications have not shown an increased rate of medullary thyroid cancer compared to the general population. One comprehensive review of clinical trials involving over 10,000 patients found no cases of MTC in people taking semaglutide.

That said, medullary thyroid cancer is extremely rare to begin with—accounting for only about 1-2% of all thyroid cancers. Because it's so uncommon, researchers need very large populations and long follow-up periods to definitively rule out any small increase in risk.

Who Should Not Take Ozempic

Even though human data is reassuring, certain people should absolutely avoid Ozempic and other GLP-1 medications due to thyroid concerns.

Personal or Family History of MTC

If you've ever been diagnosed with medullary thyroid carcinoma, or if you have a close family member (parent, sibling, child) who has had it, Ozempic is not for you. This type of thyroid cancer can run in families, and out of an abundance of caution, doctors won't prescribe GLP-1 medications to anyone with this history.

Multiple Endocrine Neoplasia Syndrome Type 2

People with a rare genetic condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) have a significantly higher risk of developing medullary thyroid cancer. If you have this condition or suspect you might based on family history, GLP-1 medications are contraindicated.

Symptoms to Watch For

While taking any GLP-1 medication, it's wise to be aware of potential thyroid-related symptoms, though they're very unlikely to occur. Contact your healthcare provider if you experience:

These symptoms can have many causes unrelated to thyroid cancer, but they warrant evaluation regardless of whether you're taking Ozempic.

Gender Considerations

Thyroid conditions in general affect women more frequently than men—women are about three times more likely to develop thyroid problems overall. However, medullary thyroid carcinoma specifically doesn't show the same gender preference as other thyroid cancers. Both men and women appear to have similar risk profiles when it comes to this rare cancer type.

Women should be aware that thyroid function can change during different life stages, including pregnancy, postpartum, and menopause. If you're taking Ozempic and experiencing symptoms like fatigue or weight changes beyond what's expected, discuss thyroid testing with your doctor to rule out common thyroid conditions unrelated to medication use.

Putting the Risk in Perspective

When making any medical decision, it helps to balance potential risks against known benefits. For many people, the metabolic benefits of GLP-1 medications are substantial: improved blood sugar control, significant weight loss, reduced cardiovascular risk, and better overall health outcomes.

The theoretical thyroid cancer risk, based on animal studies but not confirmed in humans, needs to be weighed against these very real benefits—especially if you're dealing with obesity or type 2 diabetes, conditions that carry their own serious health risks.

Your doctor can help you assess your individual risk factors. If you have no personal or family history of medullary thyroid cancer or MEN 2, the likelihood of developing thyroid cancer from Ozempic appears to be extremely low based on current evidence.

What Your Doctor Will Check

Before prescribing Ozempic or similar medications, a thorough physician will ask detailed questions about your medical history and family history, specifically looking for any thyroid cancer or MEN 2 in your relatives. Some doctors may also perform a baseline thyroid exam, feeling your neck for any existing lumps or abnormalities.

Routine thyroid cancer screening isn't typically recommended for people taking GLP-1 medications, but your doctor may check your thyroid function through blood tests, especially if you have symptoms or other risk factors for thyroid conditions.

From the Ozari Care Team

While the black box warning understandably raises concerns, the absence of confirmed cases in human studies is reassuring. Our approach is to conduct a thorough screening for any personal or family history of medullary thyroid cancer or MEN 2 before prescribing any GLP-1 medication, and to educate our patients about warning signs to monitor. For the vast majority of people without these specific risk factors, the benefits of GLP-1 therapy significantly outweigh the theoretical thyroid risks.

At Ozari Health we offer compounded Semaglutide and Tirzepatide starting at $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically reviewed by the Ozari Clinical Care Team licensed physicians specializing in metabolic health and GLP-1 therapy. Last reviewed: April 26, 2026